Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis

TL;DR

A patient with a specific EGFR mutation showed a good response to gefitinib for aggressive fibromatosis after other treatments failed.

Contribution

This is the first reported case of EGFR 19del mutation in aggressive fibromatosis responding to gefitinib.

Findings

The patient showed a sustained partial response to gefitinib after multiple treatment failures.

The main side effect was a grade 2 rash, indicating manageable toxicity.

Abstract

We present the first case of a male patient with an epidermal growth factor receptor (EGFR) 19del mutation who was diagnosed with intra-abdominal aggressive fibromatosis and familial adenomatous polyposis. We assessed the clinical response of the patient to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). A remarkable sustained partial response was achieved with the application of gefitinib after progression on multiple lines of therapy. The main adverse event of gefitinib treatment in this patient was a grade 2 rash. (Funded by the National Natural Science Foundation of China [Grant No. 82003061] and the Shanghai Sailing Program [20YF1408800] to Yanjing Guo, the Natural Science Foundation of Shanghai [Grant No. 24ZR1412800] to Xin Liu).

Figures